Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

CHIPPENHAM, England and TOKYO, June 29 /PRNewswire/ --

- Study Triggers $7.5m Milestones for Both Companies

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of activity. The study has now appeared on clinicaltrials.gov and will be recruiting in the next few weeks when the first patient first visit will trigger a $7.5 million milestone payment to both Sosei and Vectura.

The trial is a randomised, double-blind, placebo-controlled, parallel-group design, including an open-label tiotropium bromide arm, and will assess efficacy, safety and tolerability of NVA237 in patients with COPD. It will include approximately 1000 patients with moderate to severe COPD from study centres across the USA, Europe and other territories. Each patient will be randomised to receive a once-daily dose of placebo, tiotropium bromide or 50microg of NVA237 for a 52-week period. The primary endpoint of the study will be the change from baseline in FEV1 (forced expiratory volume in one second) over 12 weeks of treatment. A number of secondary endpoints will also be evaluated.

NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. Novartis intends to launch NVA237 as a once-daily monotherapy for COPD and also in combination with Novartis' investigational once-daily, long-acting beta2-agonist (LABA) indacaterol (QAB149), which was filed for approval with the regulatory authorities as a monotherapy treatment for COPD at the end of 2008. The combination of NVA237 and indacaterol is known as QVA149. NDA submissions
'/>"/>

SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... addition of the "The Corporate Reputation of ... Global Edition " report to their offering. ... Patient Perspective, is now in its fourth edition. ... published early 2015). For each annual Corporate Reputation ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 Vanda ... company focused on the development and commercialization of products ... announced it will release results for the first quarter ... market closes. The Company will host ... May 6, 2015, during which Vanda management will discuss ...
(Date:4/16/2015)... Calif. , April 16, 2015  Amgen (NASDAQ: ... its first quarter financial results on Tuesday, April 21, ... The announcement will be followed by a conference call ... in the call from Amgen will be Robert ... other members of Amgen,s senior management team. ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... the public about the,need and benefits of angioplasty, ... onslaught of,anti-stent news reports over the past few ... work and its use should,decrease. Confused by the ... the benefits of stenting. , "Doctor and patient ...
... /PRNewswire-FirstCall/ -- Vanda,Pharmaceuticals Inc. announced today that Dr. ... and Research Center in Detroit, MI,will deliver an ... for VEC-162, Vanda's balanced melatonin (MT1/MT2),receptor agonist, at ... Professional Sleep Societies, (APSS). , The Vanda presentation ...
Cached Medicine Technology:To Stent or Not: Is That the Question? 2Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the,Annual Meeting of the Associated Professional Sleep Societies 2
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Therapy Association Annual Conference to be held May ... SC. , The SCAPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:4/18/2015)... FL (PRWEB) April 18, 2015 PHOENIX, ... Hillsborough County, along with 11 other secure destruction professionals ... Secure Destruction Specialists (CSDS). He will now display “CSDS” ... exams were offered before the National Association of Information ... Illinois and another Grapevine, Texas. Of the 20 people ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... Riviera Magazine has featured board ... the Gallery of Cosmetic Surgery in Newport Beach, California ... The publication focused on his expertise in the lower ... eyelid surgery, laser resurfacing and rhinoplasty. , Dr. Sadati’s ... resulted in thousands of satisfied patients across the globe. ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... nongovernmental organizations has published a report proposing a set ... asthma clinical research. Asthma Outcomes in Clinical Research: Report ... supplement to the March 2012 issue of the ... a meeting organized by the National Institutes of Health, ...
... March 2 (HealthDay News) -- Women become less likely to ... year of college, new research finds. Declining condom use ... worse grades and who came from poorer backgrounds. "We ... pregnancies and sexually transmitted diseases, yet there has been a ...
... memory is observed in people who consume drugs containing ... team led by Giovanni Marsicano (Inserm Research Unit 862) ... has recently identified the mechanism by which these substances ... first time that the adverse effect of cannabinoids on ...
... Survivors of cancer in childhood have a higher risk ... reached by Magdalena Balcerek and her co-authors in a ... Arztebl Int 2012; 109[7] 126-31). , In a nationwide ... childhood and adolescence, the authors collected data from former ...
... Reinberg HealthDay Reporter , THURSDAY, March 1 (HealthDay ... for cervical cancer are more likely to survive if they ... suggests. Compared to women whose cervical cancer is detected ... increased their cure rate from 66 percent to more than ...
... the 27,000 plus people around the world who donate a ... donors for 10 years found that they were at no ... Led by Dr. Amit Garg, a researcher ... Sciences Centre, the results provide important safety reassurances to donors, ...
Cached Medicine News:Health News:Standardized outcome measures proposed for asthma clinical research 2Health News:College Women's Condom Use Falls During Freshman Year 2Health News:How does cannabis affect working memory? 2Health News:How does cannabis affect working memory? 3Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 2Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 3Health News:First study of its kind finds no increased risk of heart disease for kidney donors 2
The rotating stage assembly is designed to give the researcher maximum flexibility in the mounting of specimens. It can be turned to any horizontal and vertical angle via a ball joint mounting arran...
The glass knife adapter allows for the use of glass knives or ralph knives on the Vibratome. The adapter can be installed in place of the standard razor blade mounting device....
Inquire...
Inquire...
Medicine Products: